BioAtla (BCAB)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	56.52 mm	56.52 mm	56.52 mm	56.52 mm	56.52 mm	56.52 mm
Cash burn (monthly)	1.72 mm	7.06 mm	3.76 mm	7.19 mm	1.71 mm	7.09 mm
Cash used (since last report)	9.21 mm	37.92 mm	20.17 mm	38.58 mm	9.18 mm	38.06 mm
Cash remaining	47.31 mm	18.59 mm	36.35 mm	17.93 mm	47.33 mm	18.45 mm
Runway (months of cash)	27.6	2.6	9.7	2.5	27.7	2.6

Beta Read what these cash burn values mean

Financial data from BioAtla earnings reports.

Institutional ownership, Q4 2024

BCAB institutional ownership history Ownership history

70.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	72	71	+1.4%
Opened positions	21	13	+61.5%
Closed positions	20	29	-31.0%
Increased positions	16	10	+60.0%
Reduced positions	18	26	-30.8%

13F shares	Current	Prev Q	Change
Total value	14.39 bn	29.43 bn	-51.1%
Total shares	41.15 mm	36.54 mm	+12.6%
Total puts	57.00 k	33.50 k	+70.1%
Total calls	30.80 k	500.00	+6060.0%
Total put/call ratio	1.9	67.0	-97.2%

Largest owners	Shares	Value	Change
Himalaya Parent	8.68 mm	$456.69 mm	0.0%
Anson Funds Management	4.60 mm	$2.72 bn	NEW
Acorn Capital Advisors	4.03 mm	$2.38 bn	NEW
Tang Capital Partners	2.52 mm	$5.05 mm	0.0%
Highbridge Capital Management	2.51 mm	$1.48 bn	NEW
Acorn Bioventures	2.21 mm	$0.00	0.0%
Vanguard	1.83 mm	$1.08 bn	-2.8%
Zone II Healthcare	1.73 mm	$60.54 mm	0.0%
HBM Healthcare Investments	1.43 mm	$28.02 mm	0.0%
Tang Capital Management	1.37 mm	$812.35 mm	+57.2%

Largest transactions	Shares	Bought/sold	Change
Anson Funds Management	4.60 mm	+4.60 mm	NEW
Acorn Capital Advisors	4.03 mm	+4.03 mm	NEW
Soleus Capital Management	0.00	-2.52 mm	EXIT
Highbridge Capital Management	2.51 mm	+2.51 mm	NEW
Millennium Management	1.10 mm	-1.56 mm	-58.8%
PFE Pfizer	0.00	-1.37 mm	EXIT
Soleus Private Equity Fund I	628.65 k	-1.13 mm	-64.2%
MS Morgan Stanley	1.10 mm	-753.75 k	-40.6%
Boxer Capital Management	686.35 k	+686.35 k	NEW
Boxer Capital	0.00	-686.35 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

BCAB insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
16 Feb 25	Jay M PHD Short	Common Stock	Payment of exercise	Dispose F	No	No	0.46	30,911	14.22 k	1,825,372
15 Feb 25	Christian Vasquez	Common Stock	Payment of exercise	Dispose F	No	No	0.46	7,189	3.31 k	191,696
15 Feb 25	Eric Sievers	Common Stock	Payment of exercise	Dispose F	No	No	0.46	12,530	5.76 k	195,032
15 Feb 25	Richard A Waldron	Common Stock	Payment of exercise	Dispose F	No	No	0.46	10,887	5.01 k	233,263
31 Aug 24	Eric Sievers	Common Stock	Payment of exercise	Dispose F	No	No	1.77	572	1.01 k	207,562

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

12 Health Care Stocks Moving In Friday's Pre-Market Session

20 Dec 24

BioAtla Presented Data Characterizing Mutated KRAS Genotype And Clinical Outcomes In Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, A CAB-AXL-ADC, At The IASLC 2024; 1-Year OS Was 58% For Patients With NSCLC Expressing mKRAS Versus 23% For wtKRAS

16 Dec 24

Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with treatment-refractory

Press releases

From Benzinga Pro

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

20 Dec 24

SAN DIEGO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company ("BioAtla" or the "Company") focused on the development of Conditionally Active Biologic (CAB)

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

16 Dec 24